Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: February 2008
-
By Kevin E. Noonan — The latest skirmish in the struggle between innovator pharmaceutical companies (mostly in the Western world) and developing world populations is being played out in India. The outcome will depend on how the Delhi High Court interprets provisions of Indian patent law enacted to implement India’s compliance with provisions…
-
The Intellectual Property Owners Association (IPO) will be holding a conference entitled "Recent Decisions: How They Affect Your Corporate IP Practice" on March 17, 2008 in Washington, DC. Topics to be addressed at the conference include: • Changes in Patent Jurisprudence: The Aftermath of KSR — litigation and prosecution panels• Willfulness and Opinions of Counsel…
-
The American Bar Association (ABA) section of Intellectual Property Law will be holding the 23rd Annual Intellectual Property Law Conference on April 10-12, 2008 in Arlington, Virginia. Among the topics that will be covered at the conference are: • Are the Supreme Court and Federal Circuit on the Same Page For Patent Law?• What Patent…
-
The 2008 PharmaBiotech IP Summit, organized by Worldwide Business Research, will occur in Philadelphia at the Ritz-Carlton, May 28-30. The conference, "Protect Critical Patents and Drive Sustainable Growth Through IP-Driven Business Strategies," consists of two main conference days and a master class. The Patent Protection and Enforcement Masterclass occurs on May 28, and covers topics…
-
By Donald Zuhn — Yesterday, we reported on the oversight hearing on the U.S. Patent and Trademark Office held by the House Subcommittee on Courts, the Internet, and Intellectual Property. The Subcommittee heard statements from Jon Dudas, the Undersecretary of Commerce for Intellectual Property and Director of U.S. Patent and Trademark Office; Robin…
-
By Kevin E. Noonan — The U.S. Patent and Trademark Office rendered its final decision on Monday in one of the re-examinations of the Thomson stem cell patents provoked by two groups: the Public Patent Foundation (PUBPAT), headed by Dan Ravicher, and The Foundation for Taxpayer and Consumer Rights (FTCR), a California taxpayer…
-
By Donald Zuhn — On Wednesday, the House Subcommittee on Courts, the Internet, and Intellectual Property held an oversight hearing on the U.S. Patent and Trademark Office. The Subcommittee heard statements from Jon Dudas, the Undersecretary of Commerce for Intellectual Property and Director of U.S. Patent and Trademark Office; Robin Nazzaro, the Director…
-
By Kevin E. Noonan — It has been a difficult year for Genentech with regard to its blockbuster anticancer drug, Avastin® (bevacizumab). For much of the year, the company was embroiled in a dispute with the ophthalmological community over its decision (now altered) to limit sale of Avastin® for reformulation in treating age-related…
-
By Jason Derry — Sigma-Aldrich Co. has announced a licensing deal with NeuroSurvival Technologies Ltd. by which Sigma-Aldrich will be allowed to market and manufacture a marker that can detect apoptosis in vitro and in vivo. The marker, commercially known as Apo-TRACE, is one of a number of small molecules, referred to collectively…
-
By Kevin E. Noonan — Insidious (adj.): operating or proceeding in an inconspicuous or seemingly harmless way but actually with grave effect. On Saturday, The New York Times published an article analogizing two industries most readers would not have thought to be similar: the perfume industry and innovator pharmaceutical companies (see "Ahh, the…
Patent Docs 